Special Emphasis Panel for Cancer Immunotherapy R21 – CII (82)
This panel reviews R21 applications dealing with translational and clinical sciences in cancer immunotherapy. It encompasses scientific disciplines covered by the Cellar Immunotherapy of Cancer (CIC) scientific review group and a subset of disciplines covered by the Translational Immune Oncology and (TIO) and Therapeutic Immune regulation (TIO) scientific review groups.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Cellular therapies (TILs, CAR-T and TCR-engineered T cells, NK/NKT cells, dendritic cells) using immune cells as cancer treatment and their associated toxicities
- Combination therapies that contain cell therapies, radiotherapy, and immunotherapies
- Tumor vaccines of all types (protein/peptide, viral, DNA/RNA, dendritic cell, tumor cell) and formulations to induce or amplify tumor-specific immunity.
- Preclinical studies of combinations to improve the efficacy of immunotherapies
- Immunostimulatory constructs and costimulatory molecules to improve therapeutic interventions
